These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36471986)

  • 1. [Development strategy and current situation of Chinese patent medicine for children in China].
    Yang YJ; Zhu MM; Yang B; Jia XB; Feng L
    Zhongguo Zhong Yao Za Zhi; 2022 Nov; 47(21):5681-5688. PubMed ID: 36471986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis and reflection on current situation of Chinese patent medicine for children in China].
    Liu H; Chen YJ; Fu QF; Zhao SY; Nie LH; Ma R; Rong P
    Zhongguo Zhong Yao Za Zhi; 2024 Apr; 49(7):1966-1973. PubMed ID: 38812209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preparation regularity of Chinese patent medicine in Chinese Pharmacopoeia (2020 edition, Vol.Ⅰ)].
    Yin XB; Qu CH; Dong XX; Shen MR; Ni J
    Zhongguo Zhong Yao Za Zhi; 2022 Aug; 47(16):4529-4535. PubMed ID: 36046882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Scoping review of clinical evidence of Chinese patent medicines for digestive system diseases in children].
    Wu X; Dai ZQ; Xu SM; Li MM; Liao X
    Zhongguo Zhong Yao Za Zhi; 2022 Aug; 47(15):4248-4255. PubMed ID: 36046915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Technical specifications for hospital-based intensive monitoring of post-marketing Chinese patent medicine].
    Xie YM; Liao X; Jiang JJ; Zhang YL; Ma R; Zhu MJ; Zhan SY; Liu JP; Liu J; Wen ZH; Yang ZQ; He Y; Li XL
    Zhongguo Zhong Yao Za Zhi; 2019 Jul; 44(14):2896-2901. PubMed ID: 31602831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Guidelines for economic evaluation of post-marketing Chinese patent medicine].
    Shi LW; Xie YM; Nie XY; Han S; Tian X; Wang ZF
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1129-1136. PubMed ID: 38621920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Exploration and practice of post-marketing survival benefit evaluation of Chinese patent medicine for cancer].
    Xu BW; Wu JY; Li J; Zhang Y; Cao LC; Zhang XX; Gao RK
    Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1980-1987. PubMed ID: 33982508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Guidelines for post-marketing research on clinical effectiveness of Chinese patent medicines].
    Wang ZF; Xie YM; Tang JY; Zhang JH; Sun X; Yang ZQ
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(3):842-848. PubMed ID: 38621888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Technical specification for Instructions for Clinical Application of Chinese Patent Medicines in China Association of Chinese Medicine].
    Zhang XM; Sa RN; Zhang B; Zhang D; Lyu JT; Duan XJ; Lin ZJ; Guo YB
    Zhongguo Zhong Yao Za Zhi; 2021 Sep; 46(17):4563-4568. PubMed ID: 34581062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Exploration and research on comprehensive evaluation model of Chinese patent medicines supply in national essential drugs].
    Wang H; Huang LQ; Zhang XB; Zhao YP; Yang G
    Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2612-2618. PubMed ID: 28840707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research on evaluation criteria over quality as core index of high grade Chinese patent medicine].
    Liu Y; Yu HC; Zhang J; Chen C; Cheng JT; Song ZH; Liu A
    Zhongguo Zhong Yao Za Zhi; 2018 Nov; 43(21):4356-4360. PubMed ID: 30583641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world].
    Yang W; Xie Y; Zhuang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2779-82. PubMed ID: 22292363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application characteristics and situation analysis of volatile oils in database of Chinese patent medicine].
    Wang SJ; Wu ZF; Yang M; Wang YQ; Hu PY; Jie XL; Han F; Wang F
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(17):3379-83. PubMed ID: 25522633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advantages and disadvantages of production quality of Fufang Danshen Prescription based on high-quality Chinese patent medicine evaluation criteria].
    Zhao AY; Liu YP; Chen S; Guo C; Liu YZ; Wang ZG; Liu Y; Liu A
    Zhongguo Zhong Yao Za Zhi; 2022 Sep; 47(17):4814-4822. PubMed ID: 36164888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evidence mapping of clinical research on 28 Chinese patent medicines for tension-type headache].
    Guan YY; Yu XY; Li CY; Shu JZ; Tao WQ; Mi XJ; Luo XQ; Lian ZY; Zhao YH; Tang J; Liao X
    Zhongguo Zhong Yao Za Zhi; 2021 Dec; 46(24):6558-6567. PubMed ID: 34994149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Design and implementation of supply security monitoring and analysis system for Chinese patent medicines supply in national essential medicines].
    Wang H; Zhang XB; Huang LQ; Guo LP; Wang L; Zhao YP; Yang G
    Zhongguo Zhong Yao Za Zhi; 2017 Nov; 42(22):4310-4313. PubMed ID: 29318827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on establishing a methodology of comprehensive clinical evaluation for Chinese patent medicine based on health technology assessment].
    Liao X; Guo WD; Cao Z; Xu HY; Zhang YL; Zhao H; Wang YY
    Zhongguo Zhong Yao Za Zhi; 2020 Aug; 45(16):3749-3758. PubMed ID: 32893567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Construction of model for multidimensional evaluation of value and risk of Chinese patent medicine].
    Li G; Li ZK; Yang HJ; Zhan ZL; Li HM; Tang SH
    Zhongguo Zhong Yao Za Zhi; 2021 Mar; 46(5):1284-1292. PubMed ID: 33787124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thoughts on post-marketing evaluation of classical Chinese patent medicines based on clinical value].
    Song Z; Wang ZF; Wu Y; Xie YM; Yang YF; Xu Y
    Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1988-1993. PubMed ID: 33982509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China: a protocol for a systematic review and network meta-analysis.
    Hua Z; Zhai FT; Tian J; Gao CF; Xu P; Zhang F; Liu SJ; Dong K; Du XF; Zhang Z; Yang G
    BMJ Open; 2019 Sep; 9(9):e026136. PubMed ID: 31542734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.